About Diagenode
Diagenode is a company based in Seraing (Belgium) founded in 2003 was acquired by Hologic in March 2021. Diagenode has raised $8.45 million across 12 funding rounds from investors including Hologic, European Union and Capricorn Partners. The company has 99 employees. Diagenode has completed 1 acquisition, including NXT-Dx. Diagenode operates in a competitive market with competitors including Arbor Biotechnologies, Sino Biological, Singleron, GenScript and OncoDNA, among others.
- Headquarter Seraing, Belgium
- Employees 99
- SectorsHealthcare
- Website diagenode.com/en
- Social LinkedIn X Facebook
- Acquired by Hologic (Mar 2021)
- Legal Name Diagenode
Funding Insights of Diagenode
Diagenode has successfully raised a total of $8.45M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $117.75 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.45M
- Total Rounds 12
- Last Round Grant — $117,749
- Investors Count 5
Latest 10 of 12 funding rounds of Diagenode with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $117,749 | Grant | – | – | |
| Jul 2019 | $618,533 | Grant | – | – | |
| Jun 2019 | $287,039 | Grant | – | – | |
| Nov 2018 | $584,543 | Grant | – | – | |
| Sep 2018 | – | Grant | – | – | |
| Mar 2018 | $307,422 | Grant | – | – | |
| Jan 2018 | $617,295 | Grant | – | – | |
| Jan 2018 | – | Grant | – | – | |
| Jan 2018 | $300,918 | Grant | – | – | |
| Jun 2016 | $8.45M | Series A | – | SRIW, Ostbelgieninvest | – |
6 investors in total: 6 institutional.
Investors in Diagenode
Diagenode has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Hologic, European Union and Capricorn Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Buyouts are pursued by SRIW as a private equity firm. | – | sriw.be | Liege, Belgium | |
Investments are directed by Capricorn Partners into European tech ventures. | 1993 | capricorn.be | Leuven, Belgium | |
Épimède is engaged in investing in high-growth technological SMEs. | – | epimede.com | Liège, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Financing and consulting support for small and medium enterprises in Ostbelgien. | 1998 | obi.be | Eupen, Belgium | |
Diagnostic and surgical products for women's healthcare are provided. | 1985 | hologic.com | Marlborough, United States |
Investor details for Diagenode
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diagenode
Diagenode has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NXT-Dx.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Epigenetics services are offered to life science researchers. | nxt-dx.com | Gentbrugge, Belgium | 2011 | Aug 2018 | •••• |
Complete acquisition details for Diagenode
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Competitors of Diagenode
Diagenode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Arbor Biotechnologies, Sino Biological, Singleron, GenScript and OncoDNA, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| arbor.bio | 2016 | Cambridge, United States | $304.1M | 117 | Genomic technologies and drug discovery platforms are provided. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| singleron.bio | 2018 | Hagen, Germany | $84.48M | – | Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| inscripta.io | 2015 | Helsinki, Finland | $853,384 | – | Speech recognition solutions are provided by Inscripta for healthcare professionals. | |
| octant.bio | 2017 | Los Angeles, United States | $110M | 63 | Human cell interaction platform is provided for drug discovery. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application |
Detailed competitors of Diagenode
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Diagenode
The website of Diagenode (diagenode.com) receives about 19.4K visits a month.
- Monthly visits19.4K
▲ 11% vs previous month
Websites whose visitors overlap most with Diagenode. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| qiagen.com | 100% | 458.2K | #105,023 | View details | |
| abcam.com | 92% | 602.8K | #91,958 | View details | |
labequipmentparts.com | labequipmentparts.com | 91% | – | #3,155,153 | – |
| activemotif.com | 87% | 57.6K | #613,526 | View details | |
sonicator.com | sonicator.com | 86% | – | #2,280,792 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 37 similar websites and full traffic analytics for Diagenode
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 37 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Diagenode
Complete news archive for Diagenode
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Diagenode
10 companies that operate in the same segment as Diagenode (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diagenode
Diagenode was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Diagenode is headquartered in Seraing, Belgium. It is registered at Seraing, Liege, Belgium.
Diagenode is a funded company, having raised a total of $8.45M across 12 funding rounds to date. The company's 1st funding round was a Series A of $8.45M, raised on Jun 2014.
Diagenode has 99 employees.
Annual revenue of Diagenode is $19.53M as on Mar 31, 2020.
Diagenode develops epigenetics solutions and services for life science research. Its flagship product IP-Star Compact is an automated bench-top solution for high-throughput epigenetic sequencing. It has automated protocols for chromatin immunoprecipitation (ChIP), methylated DNA immunoprecipitation (MeDIP), hydroxymethylated DNA immunoprecipitation (hMeDIP), methyl-binding domain protein capture assays (MethylCap), sequential ChIP (Re-ChIP), bisulfite conversion and DNA immunoprecipitation (RNA-IP). In addition, the company provides epigenetic sequencing services, reagents, kits, bioinformatics software associated with IP-Star.
Diagenode's top competitors include Arbor Biotechnologies, Sino Biological and OncoDNA.
Diagenode has made 1 acquisition, including NXT-Dx.
Diagenode has 6 investors. Key investors include Hologic, European Union, Capricorn Partners, SRIW, and Ostbelgieninvest.
Diagenode operates through Diagenode.
Yes. Diagenode was acquired by Hologic in March 2021.